COVADIS Pilot Trial: COseal in Ventricular Assist DevIceS (COVADIS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01244321|
Recruitment Status : Unknown
Verified January 2015 by German Heart Institute.
Recruitment status was: Recruiting
First Posted : November 19, 2010
Last Update Posted : January 29, 2015
|Condition or disease|
|End-stage Heart Failure Awaiting VAD Implantation|
In the past decade the use of ventricular assist devices) (VADs) for bridging to heart transplantation (HTx) or, in some cases, to recovery of the ventricular function has increased and, during the same time, the duration of the implantation period has lengthened dramatically. When removing VADs after a long period, surgeons face severe pericardial adhesions at the mediastinum level and of the surrounding tissue due to the inflammatory response. During resternotomy, dissection of these adhesions increases surgical time and can be a source of lesions on the cardiac or vascular structures and of severe bleeding at the moment of transplantation or when the device is removed.
Many products have been used to prevent or reduce adhesions but an ideal antiadhesive treatment has remained elusive. CoSeal®, a licensed synthetic hydrogel (Baxter, USA) has been shown to reduce pericardial adhesions in a limited series of reoperations.
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Observational Model:||Case Control|
|Official Title:||A Controlled, Single-Center Clinical Pilot Study to Evaluate the Performance of CoSeal as a Barrier for Adhesion Prevention in Patients Submitted to Ventricular Assist Device VAD)|
|Study Start Date :||December 2010|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||February 2018|
Subjects with indication for LVAD implantation, meeting the requirements for LVAD implantation. Patients for whom LVAD removal is anticipated not earlier than 6 weeks after LVAD implantation.
CoSeal Control Group
Subjects who had a LVAD for more than 6 weeks.
- Presence and severity of adhesions [ Time Frame: At the moment of VAD-Removal/Transplantation (>6 weeks after VAD implantation) ]Assessment of adhesions using a scoring system, assessing six different sites.
- Bleeding [ Time Frame: At the moment of VAD-Removal/Transplantation ]Hemostasis time (START: off pump time; STOP: skin closure); bleeding volume Tansfusions of blood related products - defined as quantity of blood related product transfusions (ml) administered to the patient from skin incision to discharge or 30 days after surgery, whichever comes first, for both first and second study operation Blood loss in chest drains - defined as amount of blood lost in the chest drains from postoperative time to discharge or 30 days after surgery, whichever comes first.
- Clinical outcome [ Time Frame: At the moment of VAD removal/transplantation (>6 weeks after VAD implantation) ]
Surgery times (duration) during explantation/transplantation
- Dissection time (START: skin incision; STOP: on-pump time)
- Dissection time by region dissected, calculated as time to go to bypass (START: skin incision; STOP: initiation of bypass) by number of the investigational regions with adhesions dissected in this interval
- Time to VAD removal (START: skin incision; STOP: time of VAD removal from patient's chest at 2nd study operation)
- Length of operation (START: skin incision; STOP: chest closure).
- Adhesion related [ Time Frame: At the moment of VAD-Removal/Transplantation (>6 weeks after VAD implantation) ]
- Percentage of patients with grade 3 adhesions at VAD grafts
- Mean incidence score
- Mean adhesion severity score
- Percentage of sites free of adhesions
- Time required for adhesion dissection - pure dissection time before and after the CPB
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01244321
|Contact: Roland Hetzer, MD, PhD||++49/30/4593 email@example.com|
|Contact: Thomas Krabatsch, MD, PhD||++49/30/4593 firstname.lastname@example.org|
|Deutsches Herzzentrum Berlin||Recruiting|
|Berlin, Germany, 13353|
|Principal Investigator: Roland Hetzer, MD PhD|
|Principal Investigator:||Roland Hetzer, MD, PhD||Deutsches Herzzentrum Berlin, Germany|